Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.67 |
| ▸ | GSK3B | P49841 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 4/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22092329 | 0.98 | GSK3A (0.65) | GSK3AGSK3BMEN1KMT2AGAA | |
| SCHEMBL12359036 | 0.82 | GAA (0.57) | GSK3AGSK3BMEN1KMT2AGAA | |
| SCHEMBL14081287 | 0.82 | MEN1 (0.65) | GSK3AGSK3BMEN1KMT2AGAA | |
| SCHEMBL2674483 | 0.82 | GAA (0.57) | GSK3AGSK3BMEN1KMT2AGAA | |
| SCHEMBL22092327 | 0.82 | GAA (0.57) | GSK3AGSK3BMEN1KMT2AGAA | |
| Rhodanine-3-Acetic Acid SCHEMBL2121316 | 0.80 | GSK3A (1.00) | GSK3AGSK3BMEN1KMT2AGAA | |
| SCHEMBL5199106 | 0.80 | MEN1 (0.59) | GSK3AGSK3BMEN1KMT2AGAA | |
| SCHEMBL12465592 | 0.80 | KMT2A (0.49) | GSK3AGSK3BMEN1KMT2AGAA | |
| Rhodanine-3-Acetic Acid SCHEMBL250012 | 0.80 | GSK3A (1.00) | GSK3AGSK3BMEN1KMT2AGAA | |
| SCHEMBL12547518 | 0.79 | GAA (0.54) | GSK3AGSK3BMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003070239-A1 | BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2003-08-28 | — | — | WO | claimed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11584727-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | BSIM THERAPEUTICS, S.A. (PT) | 2023-02-21 | — | — | US | disclosed |
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220267286-A2 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM THERAPEUTICS, S.A. (PT) | 2022-08-25 | — | — | US | disclosed |
| EP-4029859-A1 | 2-OXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM THERAPEUTICS, S.A. (PT) | 2022-07-20 | — | — | EP | disclosed |
| US-11325901-B2 | Prostaglandin E synthase inhibitors and methods for utilizing the same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2022-05-10 | — | — | US | disclosed |
| US-20220041566-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM THERAPEUTICS, S.A. (PT) | 2022-02-10 | — | — | US | disclosed |
| US-7105554-B2 | Benzylidene thiazolidinediones and their use as antimycotic agents | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20040082079-A1 | Low affinity screening method | GRAFFINITY PHARMACEUTICALS AG. (DE) | 2004-04-29 | — | — | US | disclosed |
| US-20040006112-A1 | Benzylidene thiazolidinediones and their use as antimycotic agents | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2004-01-08 | — | — | US | disclosed |
| EP-1360489-A1 | LOW AFFINITY SCREENING METHOD | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2003-11-12 | — | — | EP | disclosed |
| WO-2003070239-A1 | BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2003-08-28 | — | — | WO | disclosed |
| EP-1313471-A1 | BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS | Oxford GlycoSciences (UK) Limited (GB) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002063299-A1 | LOW AFFINITY SCREENING METHOD | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002017915-A1 | BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS | OXFORD GLYCOSCIENCES (UK) LIMITED (GB) | 2002-03-07 | — | — | WO | disclosed |
| US-4933355-A | ALDOSE REDUCTASE INHIBITORS | SANKYO COMPANY LIMITED (JP) | 1990-06-12 | — | — | US | disclosed |
| EP-0337819-A1 | Thiazole derivatives, their preparation and their use in the treatment of diabetes complications | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267286-A2 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | TTR, TTPA, MTPN | GSK3A 4297/4885GSK3B 4202/4885MEN1 3061/4885 |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | GSK3A 793/4885GSK3B 716/4885MEN1 3167/4885 |
| US-11325901-B2 | Prostaglandin E synthase inhibitors and methods for utilizing the same | PTGES, PTGS1, PTGES2 | GSK3A 1886/4885GSK3B 1764/4885MEN1 4764/4885 |
| US-11584727-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | TTR, TTPA, MTPN | GSK3A 4297/4885GSK3B 4202/4885MEN1 3061/4885 |
| US-11535660-B1 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | GSK3A 1003/4885GSK3B 957/4885MEN1 3115/4885 |
| US-20040006112-A1 | Benzylidene thiazolidinediones and their use as antimycotic agents | SLC5A2, OXSR1, SLC5A1 | GSK3A 3016/4885GSK3B 2902/4885MEN1 1143/4885 |
| US-20220041566-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | TTR, TTPA, MTPN | GSK3A 4297/4885GSK3B 4202/4885MEN1 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.